Acute Coronary Syndromes: Identifying the Appropriate Patient for Prasugrel

References

• . Kushner FG, Hand M, Smith SC Jr, ; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271–2306
   PubMed Web of Science ®Google Scholar
• . Wright RS, Anderson JL, Adams CD, . 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(18):2022–2060
   PubMed Web of Science ®Google Scholar
• . Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J. 2008;156( 2 suppl):S16–S22
   PubMed Web of Science ®Google Scholar
• . Small DS, Farid NA, Payne CD, . Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475–484
   PubMed Web of Science ®Google Scholar
• . Simon T, Verstuyft C, Mary—Krause M, ; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375
   PubMed Web of Science ®Google Scholar
• . Mega JL, Close SL, Wiviott SD, . Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362
   PubMed Web of Science ®Google Scholar
• . Effient (prasugrel) tablets [package insert]. Parippany, NJ and Indianapolis, IN: Daiichi Sankyo, Inc. and Eli Lilly and Company; 2009
   Google Scholar
• . Gurbel PA, Bliden K P, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45(9):1392–1396
   PubMed Web of Science ®Google Scholar
• . Cuisset T, Frere C, Quilici J, . Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006;48(7):1339–1345
   PubMed Web of Science ®Google Scholar
• . Sabatine MS. Novel antiplatelet strategies in acute coronary syndromes. Cleve Clin J Med. 2009;76( suppl 1):S8–S15
   Google Scholar
• . US Food and Drug Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. US Food and Drug Admnistration. 2010
   Google Scholar
• . Sibbing D, Morath T, Stegherr J, . Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101(4):714–719
   PubMed Web of Science ®Google Scholar
• . Gilard M, Arnaud B, Cornily JC, . Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–260
   PubMed Web of Science ®Google Scholar
• . Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009;43(7):1266–1274
   PubMed Web of Science ®Google Scholar
• . Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55(7):1964–1968
   PubMed Web of Science ®Google Scholar
• . Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168–171
   PubMed Web of Science ®Google Scholar
• . Stockl KM, Le L, Zakharyan A, . Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170(8):704–710
   PubMed Web of Science ®Google Scholar
• . Bhatt DL, Cryer BL, Contant C F, ; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–1917
   PubMed Web of Science ®Google Scholar
• . Angiolillo DJ, Alfonso F. Clopidogrelstatin interaction: myth or reality? J Am Coll Cardiol. 2007;50(4):296–298
   PubMed Web of Science ®Google Scholar
• . Brandt JT, Close SL, Iturria SJ, . Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–2436
   PubMed Web of Science ®Google Scholar
• . Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321–341
   PubMed Web of Science ®Google Scholar
• . Best PJ, Steinhubl SR, Berger PB, . The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687–693
   PubMed Web of Science ®Google Scholar
• . Angiolillo DJ, Bernardo E, Capodanno D, . Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 2010;55(11):1139–1146
   PubMed Web of Science ®Google Scholar
• . Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104(9):1292–1295
   PubMed Web of Science ®Google Scholar
• . Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50(2):126–142
   PubMed Web of Science ®Google Scholar
• . Reinhart KM, White CM, Baker WL. Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy. 2009;29(12):1441–1451
   PubMed Web of Science ®Google Scholar
• . Plavix (clopidogrel bisulfate) tablets [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanof Pharmaceuticals Partnership; 2010
   Google Scholar
• . Wiviott SD, Trenk D, Frelinger AL, ; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923–2932
   PubMed Web of Science ®Google Scholar
• . Farid NA, Smith RL, Gillespie TA, . The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35(7):1096–1104
   PubMed Web of Science ®Google Scholar
• . Rehmel JL, Eckstein JA, Farid NA, . Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34(4):600–607
   PubMed Web of Science ®Google Scholar
• . Small DS, Farid NA, Payne CD, . Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet. 2010;49(12):777–798
   PubMed Web of Science ®Google Scholar
• . Small DS, Farid NA, Li YG, . Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24(8):2251–2257
   PubMed Web of Science ®Google Scholar
• . Sheng—Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol. 2009;104(12):3116–3117
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Desai N, Murphy SA, . Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol. 2011;108(7):905–911
   PubMed Web of Science ®Google Scholar
• . Antman EM, Wiviott SD, Murphy SA, . Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028–2033
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Antman EM, Winters KJ, ; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111(25):3366–3373
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, Angiolillo DJ, ; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626–1636
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015
   PubMed Web of Science ®Google Scholar
• . Montalescot G, Wiviott SD, Braunwald E, ; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–731
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353–1363
   PubMed Web of Science ®Google Scholar
• . Smith PK, Despotis GJ, Goodnough LT, . Mortality benefit with prasugrel in TRITON—TIMI 38 coronary artery bypass grafting (CABG) cohort risk adjusted retrospective data analysis [abstract 10881]. Presented at the American Heart Association Scientifc Sessions; November 13–17, 2010; Chicago, IL
   Google Scholar
• . Di Sciascio G, Patti G, Pasceri V, Colonna G, Mangiacapra F, Montinaro A; ARMYDA-4 RELOAD Investigators. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Eur Heart J. 2010;31(11):1337–1343
   PubMed Web of Science ®Google Scholar
• . Collet J P, Silvain J, Landivier A, . Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation. 2008;118(12):1225–1233
   PubMed Web of Science ®Google Scholar
• . Angiolillo DJ, Saucedo JF, Deraad R, ; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56(13):1017–1023
   PubMed Web of Science ®Google Scholar
• . Wallentin L, Varenhorst C, James S, . Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008; 29(1):21–30
   PubMed Web of Science ®Google Scholar
• . Angiolillo DJ, Fernandez—Ortiz A, Bernardo E, . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516
   PubMed Web of Science ®Google Scholar
• . Brilinta (ticagrelor) tablets [package insert]. Wilmington, DE: AstraZeneca LP; 2011
   Google Scholar
• . Wallentin L, Becker RC, Budaj A, . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045–1057
   PubMed Web of Science ®Google Scholar
• . Grines CL, Bonow RO, Casey DE Jr, ; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions, et al.Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49(6):734–739
   PubMed Web of Science ®Google Scholar
• . Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999;25( suppl 2):25–28
   PubMed Web of Science ®Google Scholar
• . O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel: does one size ft all? Circulation. 2006; 114(22):e600–e606
   Web of Science ®Google Scholar
• . Sugidachi A, Ogawa T, Kurihara A, . The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel refect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007;5(7):1545–1551
   PubMed Web of Science ®Google Scholar
• . von Beckerath N, Taubert D, Pogatsa—Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112(19):2946–2950
   PubMed Web of Science ®Google Scholar
• . Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111(16):2099–2106
   PubMed Web of Science ®Google Scholar
• . Siller—Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157(1):148.e1–5
   Web of Science ®Google Scholar